
- /
- Supported exchanges
- / US
- / ARVN.NASDAQ
Arvinas Inc (ARVN NASDAQ) stock market data APIs
Arvinas Inc Financial Data Overview
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Arvinas Inc data using free add-ons & libraries
Get Arvinas Inc Fundamental Data
Arvinas Inc Fundamental data includes:
- Net Revenue: 427 M
- EBITDA: -91 400 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-01
- EPS/Forecast: -0.9697
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arvinas Inc News

Arvinas CEO John Houston to retire after successor is named, will remain board chair
Arvinas, Inc. (NASDAQ:ARVN) announced Wednesday that John Houston, Ph.D., Chairperson, President and Chief Executive Officer, has notified the company of his plans to retire from his roles as Presiden...


Arvinas CEO John Houston to retire, remain as board chair
NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company with a market capitalization of $585 million, announced Wednesday that John Houston, Ph.D., will retire from his ...

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arvinas, Inc. (NASDAQ:ARVN), S...

Arvinas's SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges
Arvinas, Inc. (NASDAQ:ARVN), a biopharmaceutical company with a market capitalization of $539 million specializing in protein degradation technology, has been making waves in the oncology space with i...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.